Is JANX or DYN more profitable?

Janux Therapeutics' return on equity of -12.93% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -12.93% -12.23% Dyne Therapeutics N/A -58.28% -46.77%

Is RLAY or JANX more profitable?

Janux Therapeutics' return on equity of -12.93% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Janux Therapeutics N/A -12.93% -12.23%

Is JANX or DNLI more profitable?

Janux Therapeutics' return on equity of -12.93% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -12.93% -12.23% Denali Therapeutics N/A -52.20% -43.86%

Janux Therapeutics (JANX) Competitors

$15.33 -0.39 (-2.48%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$15.33 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

JANX vs. DYN, CPRX, RLAY, NAMS, and DNLI

Should you buy Janux Therapeutics stock or one of its competitors? MarketBeat compares Janux Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Janux Therapeutics include Dyne Therapeutics (DYN), Catalyst Pharmaceuticals (CPRX), Relay Therapeutics (RLAY), NewAmsterdam Pharma (NAMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Janux Therapeutics compare to Dyne Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Janux Therapeutics' return on equity of -12.93% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Janux Therapeutics presently has a consensus price target of $38.08, suggesting a potential upside of 148.42%. Dyne Therapeutics has a consensus price target of $34.17, suggesting a potential upside of 39.80%. Given Janux Therapeutics' higher probable upside, research analysts plainly believe Janux Therapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Dyne Therapeutics had 18 more articles in the media than Janux Therapeutics. MarketBeat recorded 19 mentions for Dyne Therapeutics and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.81 beat Dyne Therapeutics' score of 0.64 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Very Positive
Dyne Therapeutics	Positive

Janux Therapeutics has higher revenue and earnings than Dyne Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$13.73M	68.08	-$113.62M	-$1.84	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Janux Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Janux Therapeutics beats Dyne Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Catalyst Pharmaceuticals?

Janux Therapeutics (NASDAQ:JANX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Catalyst Pharmaceuticals had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.81 beat Catalyst Pharmaceuticals' score of 1.63 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Very Positive
Catalyst Pharmaceuticals	Very Positive

Janux Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Janux Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$13.73M	68.08	-$113.62M	-$1.84	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Janux Therapeutics presently has a consensus target price of $38.08, indicating a potential upside of 148.42%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Janux Therapeutics' higher probable upside, research analysts clearly believe Janux Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Summary

Catalyst Pharmaceuticals beats Janux Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Janux Therapeutics compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Janux Therapeutics' return on equity of -12.93% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Janux Therapeutics	N/A	-12.93%	-12.23%

Relay Therapeutics presently has a consensus price target of $24.92, suggesting a potential upside of 35.12%. Janux Therapeutics has a consensus price target of $38.08, suggesting a potential upside of 148.42%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Relay Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Relay Therapeutics and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.81 beat Relay Therapeutics' score of 0.39 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Relay Therapeutics	Neutral
Janux Therapeutics	Very Positive

Relay Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.68M	330.91	-$276.48M	-$1.57	N/A
Janux Therapeutics	$13.73M	68.08	-$113.62M	-$1.84	N/A

Summary

Janux Therapeutics beats Relay Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to NewAmsterdam Pharma?

Janux Therapeutics (NASDAQ:JANX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Janux Therapeutics presently has a consensus price target of $38.08, suggesting a potential upside of 148.42%. NewAmsterdam Pharma has a consensus price target of $49.42, suggesting a potential upside of 66.72%. Given Janux Therapeutics' higher probable upside, equities research analysts clearly believe Janux Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Janux Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. Janux Therapeutics' return on equity of -12.93% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

In the previous week, NewAmsterdam Pharma had 9 more articles in the media than Janux Therapeutics. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.81 beat NewAmsterdam Pharma's score of 1.10 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Very Positive
NewAmsterdam Pharma	Positive

Janux Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$13.73M	68.08	-$113.62M	-$1.84	N/A
NewAmsterdam Pharma	$22.57M	153.56	-$203.82M	-$1.79	N/A

Janux Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats Janux Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Janux Therapeutics compare to Denali Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Denali Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Denali Therapeutics and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.81 beat Denali Therapeutics' score of 0.71 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Very Positive
Denali Therapeutics	Positive

Janux Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Janux Therapeutics' return on equity of -12.93% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Denali Therapeutics	N/A	-52.20%	-43.86%

Janux Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$13.73M	68.08	-$113.62M	-$1.84	N/A
Denali Therapeutics	$330.53M	11.10	-$512.54M	-$2.88	N/A

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics presently has a consensus target price of $38.08, suggesting a potential upside of 148.42%. Denali Therapeutics has a consensus target price of $35.17, suggesting a potential upside of 52.17%. Given Janux Therapeutics' higher probable upside, equities research analysts clearly believe Janux Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Janux Therapeutics and Denali Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$934.89M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-8.33	21.29	27.11	23.64
Price / Sales	68.08	170.12	517.09	89.57
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.96	7.88	10.28	6.07
Net Income	-$113.62M	$23.86M	$3.60B	$331.99M
7 Day Performance	-5.72%	-3.82%	-1.27%	-0.63%
1 Month Performance	5.14%	-2.61%	-0.37%	-2.00%
1 Year Performance	-40.95%	32.79%	18.30%	13.62%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	4.0539 of 5 stars	$15.33 -2.5%	$38.08 +148.4%	-41.0%	$934.89M	$13.73M	N/A	30	Positive News
DYN Dyne Therapeutics	3.3037 of 5 stars	$23.45 -1.2%	$34.17 +45.7%	+164.5%	$3.92B	N/A	N/A	100	Upcoming Earnings Analyst Forecast Gap Down
CPRX Catalyst Pharmaceuticals	4.415 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	News Coverage Positive News Short Interest Decrease
RLAY Relay Therapeutics	2.9544 of 5 stars	$19.18 -3.7%	$24.17 +26.0%	+401.1%	$3.81B	$15.35M	N/A	330	News Coverage Analyst Forecast
NAMS NewAmsterdam Pharma	2.9051 of 5 stars	$29.67 -6.3%	$49.42 +66.6%	+26.7%	$3.70B	$22.50M	N/A	4	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. DYN, CPRX, RLAY, NAMS, and DNLI

How does Janux Therapeutics compare to Dyne Therapeutics?

Summary

How does Janux Therapeutics compare to Catalyst Pharmaceuticals?

Summary

How does Janux Therapeutics compare to Relay Therapeutics?

Summary

How does Janux Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Janux Therapeutics compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. DYN, CPRX, RLAY, NAMS, and DNLI

How does Janux Therapeutics compare to Dyne Therapeutics?

Is JANX or DYN more profitable?

Do analysts rate JANX or DYN?

Do institutionals and insiders hold more shares of JANX or DYN?

Does the media prefer JANX or DYN?

Which has higher valuation & earnings, JANX or DYN?

Which has more risk & volatility, JANX or DYN?

Summary

How does Janux Therapeutics compare to Catalyst Pharmaceuticals?

Does the media refer more to JANX or CPRX?

Which has more risk & volatility, JANX or CPRX?

Is JANX or CPRX more profitable?

Which has stronger valuation and earnings, JANX or CPRX?

Do insiders & institutionals have more ownership in JANX or CPRX?

Do analysts prefer JANX or CPRX?

Summary

How does Janux Therapeutics compare to Relay Therapeutics?

Is RLAY or JANX more profitable?

Do analysts recommend RLAY or JANX?

Does the media favor RLAY or JANX?

Which has more risk & volatility, RLAY or JANX?

Do institutionals & insiders hold more shares of RLAY or JANX?

Which has preferable valuation and earnings, RLAY or JANX?

Summary

How does Janux Therapeutics compare to NewAmsterdam Pharma?

Do insiders and institutionals hold more shares of JANX or NAMS?

Do analysts rate JANX or NAMS?

Is JANX or NAMS more profitable?

Does the media prefer JANX or NAMS?

Which has higher valuation and earnings, JANX or NAMS?

Which has more risk and volatility, JANX or NAMS?

Summary

How does Janux Therapeutics compare to Denali Therapeutics?

Does the media refer more to JANX or DNLI?

Which has more volatility & risk, JANX or DNLI?

Is JANX or DNLI more profitable?

Which has preferable earnings and valuation, JANX or DNLI?

Do insiders & institutionals hold more shares of JANX or DNLI?

Do analysts recommend JANX or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools